Previous 10 | Next 10 |
Gainers: XPO +15.6% . OSMT +15.1% . SYRS +3.1% . SAVE +2.1% . CRSP +1.9% . More news on: XPO Logistics, Inc., Osmotica Pharmaceuticals plc, Syros Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Shares of Syros Pharmaceuticals (NASDAQ: SYRS) are soaring today, up by 15.7% as of 11:04 a.m. EST, after the company announced that Mark Alles is joining its board of directors. Alles previously served as CEO of Celgene prior to its acquisition by Bristol-Myers Squibb . The appointment of...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company’s Board of Directors. Mr. Alles is a recognized biopharmaceutical executive with a proven record of building...
CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...
Gainers: Inpixon (NASDAQ: INPX ) +68% . More news on: Inpixon, Mirum Pharmaceuticals, Inc., YayYo, Inc., Stocks on the move, Read more ...
Syros Pharmaceuticals (NASDAQ: SYRS ) ( +6% premarket) and Global Blood Therapeutics (NASDAQ: GBT ) ( -6% premarket) will collaborate to discover, develop and commercialize new treatments for sickle cell disease and beta thalassemia. More news on: Syros Pharmaceuticals, Inc.,...
YayYo (NASDAQ: YAYO ) +39% on entering into a new fleet partnership with LMP Automotive Holdings. More news on: YayYo, Inc., Solid Biosciences Inc., ASLAN Pharmaceuticals Limited, Stocks on the move, Read more ...
Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered into a $150 million loan ag...
Collaboration Combines GBT’s Therapeutic Area Leadership with Power of Syros’ Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical Research Funding and Milestone Payments ...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on h...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...